45 completed, 12 terminated, 4 unknown, 2 withdrawn. 63 Phase 2, 20 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 63 | Completed 45, Terminated 12, Unknown 4, Withdrawn 2 |
| Phase 1 | 20 | Completed 12, Unknown 4, Terminated 3, Withdrawn 1 |
Follow Recurrent Adult Diffuse Large Cell Lymphoma: new trials by email Literature Review of Recurrent Adult Diffuse Large Cell Lymphoma trials Research Report on Recurrent Adult Diffuse Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma CD19.CAR-T cells - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2015-12-01 | 2019-02-27 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma alisertib, rituximab, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 14 | 2013-05-21 | 2018-06-06 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan - Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Completed | University of Arizona | 5 | 2012-08-31 | 2018-08-28 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant allogeneic cytomegalovirus-specific cytotoxic T lymphocytes - Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 1 | 2012-04-01 | 2017-02-15 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma Ofatumumab, Bortezomib - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2011-10-01 | 2014-07-30 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma panobinostat, laboratory biomarker analysis, western blotting - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Mayo Clinic | 41 | 2011-01-17 | 2022-05-24 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma everolimus, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 58 | 2011-01-10 | 2020-10-22 |
Showing 20 of 63. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (63) · Lymphoma, Mantle-Cell (54) · Lymphoma, Follicular (50) · Leukemia, Lymphocytic, Chronic, B-Cell (45) · Burkitt Lymphoma (42) · Lymphoma, B-Cell, Marginal Zone (42) · Waldenstrom Macroglobulinemia (39) · Lymphoma, Non-Hodgkin (38) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Lymphoma, Large-Cell, Immunoblastic (36) · Hodgkin Disease (31) · Lymphoma, Large-Cell, Anaplastic (30) · Mycosis Fungoides (28) · Sezary Syndrome (28) · Lymphoma, T-Cell, Cutaneous (27)
Hemic and Lymphatic Diseases (63) · Immune System Diseases (63) · Immunoproliferative Disorders (63) · Lymphatic Diseases (63) · Lymphoma (63) · Lymphoproliferative Disorders (63) · Neoplasms by Histologic Type (63) · Neoplasms (62) · Lymphoma, B-Cell (61) · Hematologic Diseases (50) · Leukemia (48) · Leukemia, Lymphoid (48) · Chronic Disease (45) · Disease Attributes (45) · Leukemia, B-Cell (45)
Rituximab (17) · Mycophenolic Acid (13) · Whole-Body Irradiation (13) · fludarabine phosphate (13) · Peripheral Blood Stem Cell Transplantation (12) · Cyclosporine (10) · Cyclophosphamide (8) · Tacrolimus (8) · Etoposide (5) · ibritumomab tiuxetan (5) · Busulfan (4) · Carboplatin (4) · Methotrexate (4) · merphos (4) · Bendamustine Hydrochloride (3)
National Cancer Institute (NCI) (22) · Fred Hutchinson Cancer Center (17) · Mayo Clinic (5) · Chinese PLA General Hospital (3) · University of Washington (3) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Arizona (1) · University of Chicago (1) · University of Medicine and Dentistry of New Jersey (1) · University of Nebraska (1)
United States (56) · China (5) · Italy (5) · Germany (2) · Canada (1) · Denmark (1)
Ajay Gopal (7) · Brenda Sandmaier (4) · David Maloney (3) · Sonali Smith (3) · Anas Younes (2) · Alison Stopeck (1) · Barbara Pro (1) · Bo Zhu, M.D., Ph.D. (1) · Brenda Cooper (1) · Brenda Cooper, MD (1) · Cameron Turtle (1) · Craig Okada (1) · Craig Reeder, M.D. (1) · Daniel O. Persky, MD (1) · David Scadden (1)
PMID 32499241, PMID 34515338, PMID 19900571, PMID 20837940, PMID 21508413, PMID 24241210, PMID 25085357, PMID 25444722, PMID 26213141, PMID 26764356, PMID 28314788, PMID 28869931, PMID 29263894, PMID 30454872, PMID 30596402, PMID 31481800, PMID 32245502, PMID 41804087
P30CA015704 (12), N01CM62202 (5), N01CM62201 (4), P01CA018029 (4), P30CA015083 (4), N01CM17003 (3), P01CA078902 (3), P30CA014599 (3), P01CA044991 (2), P30CA016672 (2), U10CA032102 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM17107 (1)